Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | KRAS | P01116 | 8/20 | 0.68 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.60 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742889 | 0.93 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL16144148 | 0.93 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL8202050 | 0.91 | NT5E (0.83) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL21742748 | 0.90 | TGM2 (0.78) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL16113890 | 0.90 | TGM2 (0.78) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL16113893 | 0.90 | TGM2 (0.78) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL24322609 | 0.90 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL21171613 | 0.90 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL18769050 | 0.90 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 | |
| SCHEMBL18769051 | 0.90 | NT5E (0.75) | NT5ETGM2KRASFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3169335-A2 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-1032708-A4 | NUCLEIC ACID LIGANDS OF TISSUE TARGET | SCHERING AG (DE) | 2004-09-15 | — | — | EP | disclosed |
| US-6127119-A | DETECTING NUCLEOTIDE SEQUENCES WITH RECEPTIVITY TO BLOOD VESSELS; INCUBATING MIXTURE OF NUCLEOTIDE SEQUENCES WITH BLOOD VESSELS, PARTITIONING SEQUENCES WITH AMPLIFIED AFFINITY, AMPLIFYING NUCLEOTIDE SEQUENCES | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1032708-A1 | NUCLEIC ACID LIGANDS OF TISSUE TARGET | NeXstar Pharmaceuticals, Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999027138-A1 | NUCLEIC ACID LIGANDS OF TISSUE TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407683-B2 | Circular polynucleotides | POLN, POLRMT, POLI | NT5E 139/4885TGM2 4508/4885KRAS 1040/4885 |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | POLN, POLRMT, POLI | NT5E 139/4885TGM2 4508/4885KRAS 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.